Pills, pricing and growth

Warfarin, toxin of choice to rid us of nasty rats, is also the drug of choice to stop you having a blood clot. Liberally prescribed on the NHS, the tablets cost peanuts. However it’s not perfect. You can’t take it with other common medicines such as aspirin and thyroxine, you can’t eat your greens (spinach, Brussels sprouts, Swiss chard, green beans, asparagus, broccoli etc) and it requires regular blood tests to ensure the dose is ok. These checks also cost the NHS money – in some cases patient’s require weekly appointments with a nurse.

So that’s why companies have been trying to find something better.  Pfizer and BMS have just produced more  results from their contribution. They are not the only ones, but the point is, it will be much more expensive than warfarin, so will our doctors prescribe it even though it will reduce staff costs? And how will patients know to ask for it? Will the government be giving power as well as information?

Meanwhile in Germany, a new drug for Diabetes is sitting on the shelf because changes to the government’s pricing mechanism mean that the proposed price could be so low it might not be worth the producers selling it there. The repercussions are huge: loss of revenue for the company; no access to the medicine for patients; loss of clinical trials opportunities in the future (as new medicines are compared the best in field); an implicit message to industry that innovation isn’t valued.

There are important reasons to remember that there is more to medicines than taking a pill: ensuring we don’t disincentivise risk-taking and the innovative steps that can turn into a breakthrough; offering choice; remembering that although drug development is global, without a strong science base and a fair market we will lose out both economically and medically. If George Osborne is serious about science and innovation being the priority for growth (and the Life Sciences Autumn Package questions are taken seriously), then he also mustn’t ignore DH plans for changes to pricing of medicines. They might not think that pills, pricing and growth are connected, but believing them would risk our recovery.

 

 

Advertisements

About Julia Manning

Julia Manning is a social pioneer, writer, campaigner and commentator. Formerly a clinical optometrist specialising in diabetes and visual impairment, she is the founder and Director of 2020health, an independent, social enterprise Think Tank whose aim is to Make Health Personal and Social. 2020health has through research, events and campaigning influenced opinion and action in fields as diverse as bioethics, alcohol, emerging technologies, fraud, education, consumer technology and vaccination. In 2014, 2020health were founding partners of the Health Tech and You Awards with Axa PPP and the Design Museum. Since 2016, 2020health has increasingly focused on digital health and public health in the community. Julia is a Fellow of the RSA and now also a part-time PhD student at the UCL Interaction Centre, studying the use of digital technology for stress management in the workplace. Julia has shared 2020health's research widely in the media (BBC News, ITV, Channel 5 News, BBC 1′s The Big Questions & Victoria Derbyshire, BBC Radio 4 Today, PM and Woman's Hour, LBC) and has taken part in debates and contributed to BBC’s Newsnight, Panorama, You and Yours and ITV’s The Week.
This entry was posted in Business, Drugs, Innovation, Uncategorized and tagged , , , , , , . Bookmark the permalink.

Leave a Reply

Please log in using one of these methods to post your comment:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

w

Connecting to %s